Regulatory Affairs and Pharmacovigilance in Italy: A Practical Guide for Pharma Companies

Introduction

Italy is an important pharmaceutical market within the European Union (EU), offering opportunities for companies developing, manufacturing and commercialising medicinal products. However, entering and maintaining a presence in the Italian market requires a clear understanding of both national requirements and the wider European regulatory framework.

The Italian Medicines Agency (AIFA) plays a central role in national medicines authorisation, safety monitoring and regulatory oversight. At the same time, EU legislation and European Medicines Agency (EMA) guidance shape many requirements for marketing authorisation holders (MAHs).

For pharmaceutical companies, regulatory affairs and pharmacovigilance must work together throughout a product’s lifecycle. Effective coordination supports compliant submissions, reliable safety monitoring and timely responses to regulatory changes.

1. Understanding Italy’s Pharmaceutical Regulatory Framework

AIFA is the national authority responsible for important aspects of medicinal product regulation in Italy. It assesses applications, oversees relevant regulatory procedures and monitors the safety of medicines available in the country.

Companies seeking to market a medicine in Italy must identify the appropriate authorisation route. Depending on the product and business strategy, this may involve:

• National procedure: An application assessed for authorisation in Italy.
• Mutual recognition procedure (MRP): Extends an existing national authorisation to other EU Member States.
• Decentralised procedure (DCP): Allows simultaneous applications in multiple Member States for products not yet authorised in the EU.
• Centralised procedure: Results in a single EU-wide authorisation granted by the European Commission following EMA assessment.

The choice depends on product characteristics, regulatory eligibility and the intended geographic market. Companies should assess these factors early to avoid unnecessary procedural delays.

Organisations planning market entry can review the scope of Regulatory Affairs Services in Italy when evaluating country-specific regulatory responsibilities and submission requirements.

2. Marketing Authorisation Pathways in Italy

A marketing authorisation application (MAA) must provide evidence that a medicinal product meets applicable quality, safety and efficacy standards. The Common Technical Document (CTD) provides the harmonised structure for presenting this evidence.

The dossier generally includes five modules:

• Module 1: Regional administrative information and product information.
• Module 2: Quality, non-clinical and clinical summaries.
• Module 3: Quality and manufacturing data.
• Module 4: Non-clinical study reports.
• Module 5: Clinical study reports.

The content must be accurate, consistent and aligned with the applicable EU and Italian requirements. Companies should also ensure that manufacturing, labelling and product information documents remain consistent across the dossier.

Electronic Common Technical Document (eCTD) submissions require particular attention to document structure, technical validation, lifecycle sequences and submission readiness. Errors in publishing or dossier organisation can lead to validation issues and additional work.

A structured approach to eCTD Publishing and Submission Services can help companies manage technical publishing requirements and maintain submission consistency.

3. Pharmacovigilance Responsibilities and Safety Monitoring

Regulatory compliance does not end when a medicine receives marketing authorisation. MAHs must maintain pharmacovigilance systems that identify, assess and manage potential safety risks throughout the product lifecycle.

In Italy, pharmacovigilance operates within the EU legal framework, supported by AIFA and EMA processes. Core responsibilities include:

• Collecting and assessing suspected adverse reaction reports.
• Submitting applicable individual case safety reports (ICSRs) through the required systems.
• Maintaining the pharmacovigilance system master file (PSMF).
• Preparing and maintaining risk management plans (RMPs), where required.
• Managing periodic safety reports and signal detection activities.
• Implementing and evaluating risk-minimisation measures.

The EU’s Good Pharmacovigilance Practices (GVP) provide guidance on the systems and processes that MAHs should maintain. The qualified person responsible for pharmacovigilance (QPPV) must meet applicable EU requirements, and the pharmacovigilance system should be inspection-ready.

AIFA conducts GVP inspections that may examine records, procedures, delegated activities and the PSMF. Therefore, companies should maintain clear responsibilities, documented processes, training records and effective oversight of service providers.

Businesses reviewing local safety obligations can explore Pharmacovigilance Services in Italy as part of their assessment of country-level pharmacovigilance needs.

4. Managing Regulatory Submissions and Product Information

Post-authorisation activities are a continuous part of regulatory management. Changes to manufacturing processes, product composition, safety information or administrative details may require regulatory assessment and submission.

Companies should maintain procedures to identify changes, determine the appropriate variation category and submit supporting documentation within applicable timelines.

Product information also requires ongoing control. The Summary of Product Characteristics (SmPC), package leaflet and labelling must reflect approved information and applicable safety updates. Translations and country-specific packaging requirements should be reviewed carefully before implementation.

Well-managed Regulatory Labeling Services can support document consistency, version control and alignment between approved product information and market-ready materials.

5. Building an Effective Compliance Strategy

A sustainable regulatory strategy connects submission planning, safety monitoring and lifecycle management rather than treating them as separate functions.

Pharmaceutical companies operating in Italy should consider the following practices:

• Maintain regulatory intelligence: Monitor AIFA, EMA and European Commission updates that may affect products or procedures.
• Establish clear accountability: Define responsibilities across regulatory affairs, quality, medical and pharmacovigilance teams.
• Control documentation: Maintain accurate records, approved versions and traceable change histories.
• Review outsourced activities: Ensure vendors operate under documented agreements, defined procedures and appropriate oversight.
• Prepare for inspections: Keep evidence of compliance accessible and ensure personnel understand their responsibilities.
• Coordinate safety and regulatory changes: Assess whether new safety information requires updates to product information, risk management measures or regulatory submissions.

The EU regulatory environment continues to evolve. For example, Commission Implementing Regulation (EU) 2025/1466 amended aspects of the pharmacovigilance implementing framework, and EMA has indicated that related GVP guidance will be updated. Companies should therefore monitor current guidance rather than relying solely on historical procedures.

Conclusion

Regulatory affairs and pharmacovigilance are essential to the successful commercialisation and continued compliance of medicinal products in Italy. Companies must understand AIFA procedures, select appropriate EU authorisation pathways, maintain technically sound submissions and operate effective post-authorisation safety systems.

A coordinated approach helps organisations manage regulatory obligations, respond to safety developments and maintain reliable product information throughout the lifecycle. Regular review of official AIFA and EMA guidance remains important as requirements and implementation practices evolve.

Why Choose DDReg as your Consulting Partner

For organisations assessing regulatory processes across markets, Life Science Consulting Services can provide a starting point for exploring regulatory and compliance topics. Teams monitoring changing requirements may also find Regulatory Intelligence Tools useful for tracking regulatory developments, while Regulatory Affairs Lifecycle Management offers a resource for understanding how lifecycle activities can be organised and monitored.